DNTH vs COGT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DNTH · Dianthus Therapeutics$86.03 ▲ 3.64%
COGT · Cogent Biosciences$31.65 ▲ 6.98%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DNTH +135.0%
- COGT -2.5%
Head to head
| Metric | DNTH | COGT |
|---|---|---|
| Price | $86.03 | $31.65 |
| Change today | ▲ 3.64% | ▲ 6.98% |
| Market cap | $4.84B | $5.49B |
| Return, 3 months | -23.1% | -23.8% |
| Return, year to date | +108.8% | -10.9% |
| Return, 1 year | +137.1% | +113.5% |
| P/E (TTM) | – | – |
| P/B | 3.9 | 12.2 |
| P/E percentile vs own 5y | 11th | 18th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +294.3% | – |
| Net profit growth (YoY) | -58.8% | -31.1% |
| Gross margin | – | – |
| Operating margin | -11,441.4% | – |
| Net margin | -10,097.0% | – |
| Return on equity | -26.1% | -146.5% |
| Analyst target vs. price | +63.1% | +73.4% |
| Analyst buy share | 100% | 89% |
| RSI (14) | 55 | 52 |
| 30-day volatility | 39.5% | 47.6% |
| Max drawdown, 1 year | -37.8% | -34.4% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- COGT is the largest of the group by market value.
- DNTH has returned the most over the past year.
- DNTH has been the calmest stock over the last 30 days.